A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma

• Published in: Journal of experimental & clinical cancer research Vol. 40; no. 1; p. 189
• Main Authors: Mlakar, Vid, Morel, Edouard, Mlakar, Simona Jurkovic, Ansari, Marc, Gumy-Pause, Fabienne
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08-06-2021; BioMed Central; BMC
• Subjects: ALK; Bone marrow; Cancer; Cancer therapies; Clinical trials; Development and progression; ERK1/2; Gene amplification; Humans; Kinases; MAP Kinase Signaling System - genetics; Medical prognosis; MEK1/2; Mutation; Neuroblastoma; Neuroblastoma - genetics; Oncology, Experimental; Proteins; RAS; RAS-MAPK; Review; Signal transduction; Software; Tumors; Canada; United States > US; Redwood City California; ALK; ERK1/2; Inhibitors; MEK1/2; RAS; Neuroblastoma; RASopathie; RAS-MAPK
• ISSN: 1756-9966; 0392-9078; 1756-9966
• DOI: 10.1186/s13046-021-01967-x

Neuroblastoma is the most common extra-cranial solid tumor in children, representing approximately 8% of all malignant childhood tumors and 15% of pediatric cancer-related deaths. Recent sequencing and transcriptomics studies have demonstrated the RAS-MAPK pathway's contribution to the development and progression of neuroblastoma. This review compiles up-to-date evidence of this pathway's involvement in neuroblastoma. We discuss the RAS-MAPK pathway's general functioning, the clinical implications of its deregulation in neuroblastoma, and current promising therapeutics targeting proteins involved in signaling.